Strands

Premium

Cenix Begins Target Validation Work for AstraZeneca

Cenix BioScience announced this week that it has begun a second research project under an existing arrangement with AstraZeneca.

According to Cenix, the new project will focus on cell-based studies to advance the validation of novel oncology-target candidates recently identified by the company in RNAi screens conducted for AstraZeneca.

Specific terms of the new agreement were not disclosed.


RXi Q4 Losses Rise on Higher R&D Spending, Delivery Technology License

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.